Theralase receives award for cancer technology
By Maria DiDanieli
Sept. 30, Toronto, Ont. – Theralase Technologies Inc. has been awarded a 2010 Breakthrough Award by Popular Mechanics Magazine for its work with lasers in the destruction of cancer cells.
Sept. 30, Toronto, Ont. – Theralase Technologies Inc. has been awarded a
2010 Breakthrough Award by Popular Mechanics Magazine for its work with
lasers in the destruction of cancer cells.
Popular Mechanics Magazine's "Breakthrough Awards" is honouring the year's most impressive advances in science and technology.
Theralase Technologies Inc. President and CEO, Roger Dumoulin-White joined Karen Brewer and Brenda Winkel of Virginia Tech to receive the award at the Hearst Tower in New York on October 5, 2010.
Dumoulin-White stated, "It is humbling to be acknowledged by such a prestigious magazine as Popular Mechanics, a magazine which portrayed technology that I was always awe-struck with as a child. We believe our work with patented Theralase lasers and PDCs for the destruction of cancer cells is truly groundbreaking and I speak on behalf of the entire company to say we are very excited to receive this award. We plan to continue our work toward commercializing this technology for the real and tangible benefit of all."
Lothar Lilge, Ph.D., the principal investigator of the PDCs, a published expert on PDCs and a leading researcher at the world renowned Ontario Cancer Institute located at Princess Margaret Hospital, University Health Network stated, "We are currently awaiting the final approval to commence testing the PDCs in a live small animal model to evaluate toxicity. In vitro, the lead PDCs have demonstrated low reaction without the presence of light, proving the safety of the compounds and a moderate to high ability to destroy cancer cells when subjected to light, indicating their innate ability to destroy cancer cells. Due to the ability of these PDCs to work in low oxygen environments, they will be ideally suited in the destruction of solid core tumours, such as breast and prostate cancers. In conjunction with Virginia Tech, we will optimize the lead compounds for cancer cell destruction. Successful completion of a small animal pre-clinical study, and the knowledge accumulated from it in regards to PDC light dose interactions, such as toxicology, safety and efficacy, will pave the way for companion animal treatments and early human trials under FDA Phase 1, as early as 2011."
For more information, visit the corporate or regulatory website at www.theralase.com or www.sedar.com.